NASDAQ:NVNO enVVeno Medical (NVNO) Stock Price, News & Analysis $10.95 +0.80 (+7.88%) Closing price 04:00 PM EasternExtended Trading$10.92 -0.03 (-0.24%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About enVVeno Medical Stock (NASDAQ:NVNO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get enVVeno Medical alerts:Sign Up Key Stats Today's Range$9.74▼$10.9550-Day Range$9.32▼$13.0552-Week Range$8.67▼$196.70Volume7,883 shsAverage Volume17,993 shsMarket Capitalization$7.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview enVVeno Medical, Inc. is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort. The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion. By housing the catheter entry point beneath the skin, the system is engineered to reduce catheter‐related bloodstream infections (CRBSIs) and to improve patient mobility and quality of life during extended treatment regimens. enVVeno Medical is currently conducting clinical studies to gather safety and performance data in collaboration with U.S. healthcare institutions. Founded in 2018 and headquartered in Durham, North Carolina, enVVeno Medical serves hospitals, infusion centers, and home healthcare providers across the United States. The company is led by President and Chief Executive Officer Frank Douette, whose leadership team brings extensive experience in medical device development, regulatory affairs and commercialization strategies. The board and management draw on backgrounds in cardiovascular and vascular access markets to guide product development and regulatory pathways. As a NASDAQ‐listed entity, enVVeno Medical is positioned to advance its Freedom platform through pivotal clinical trials and toward regulatory approval. By targeting an estimated multi‐billion dollar vascular access market, the company seeks to offer clinicians and patients a safer, more convenient option for long‐term intravenous therapy and to establish a new standard in vascular access care.AI Generated. May Contain Errors. Read More enVVeno Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreNVNO MarketRank™: enVVeno Medical scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingenVVeno Medical has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageenVVeno Medical has only been the subject of 1 research reports in the past 90 days.Read more about enVVeno Medical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of enVVeno Medical is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of enVVeno Medical is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioenVVeno Medical has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about enVVeno Medical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.63% of the float of enVVeno Medical has been sold short.Short Interest Ratio / Days to CoverenVVeno Medical has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in enVVeno Medical has recently decreased by 20.75%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldenVVeno Medical does not currently pay a dividend.Dividend GrowthenVVeno Medical does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for NVNO on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, enVVeno Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,613.00 in company stock.Percentage Held by Insiders15.00% of the stock of enVVeno Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions34.71% of the stock of enVVeno Medical is held by institutions.Read more about enVVeno Medical's insider trading history. Receive NVNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVNO Stock News HeadlinesenVVeno Medical Corporation: enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" SegmentMay 12, 2026 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe SystemMay 7, 2026 | finanznachrichten.deA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 20 at 1:00 AM | Porter & Company (Ad)One enVVeno Medical Insider Raised Their Stake In The Previous YearMay 6, 2026 | finance.yahoo.comenVVeno Medical CorporationApril 5, 2026 | cnn.comNorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic AlternativesMarch 3, 2026 | financialpost.comFNorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic AlternativesMarch 3, 2026 | globenewswire.comenVVeno Medical Regains Nasdaq Compliance, Supports 2026 PlansFebruary 7, 2026 | theglobeandmail.comSee More Headlines NVNO Stock Analysis - Frequently Asked Questions How have NVNO shares performed this year? enVVeno Medical's stock was trading at $11.2280 on January 1st, 2026. Since then, NVNO shares have decreased by 2.5% and is now trading at $10.95. How were enVVeno Medical's earnings last quarter? enVVeno Medical Corporation (NASDAQ:NVNO) issued its earnings results on Thursday, May, 7th. The company reported ($5.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.40) by $2.51. When did enVVeno Medical's stock split? enVVeno Medical shares reverse split before market open on Tuesday, January 20th 2026.A 1-35 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 19th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did enVVeno Medical IPO? enVVeno Medical (NVNO) raised $10 million in an initial public offering (IPO) on Thursday, May 31st 2018. The company issued 1,500,000 shares at a price of $6.00-$8.00 per share. How do I buy shares of enVVeno Medical? Shares of NVNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of enVVeno Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that enVVeno Medical investors own include Bionano Genomics (BNGO), VBI Vaccines (VBIV), Avino Silver & Gold Mines (ASM), Amarin (AMRN), Coherus Oncology (CHRS), Exelixis (EXEL) and Fortress Biotech (FBIO). Company Calendar Last Earnings5/07/2026Today5/20/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 NVNO's financial health is in the Red zone, according to TradeSmith. NVNO has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:NVNO CIK1661053 Webwww.hancockjaffe.com Phone(949) 261-2900Fax949-261-2992Employees30Year Founded1987Profitability EPS (Trailing Twelve Months)($25.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.47 million Net MarginsN/A Pretax MarginN/A Return on Equity-66.39% Return on Assets-60.42% Debt Debt-to-Equity RatioN/A Current Ratio11.89 Quick Ratio11.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$35.57 per share Price / Book0.31Miscellaneous Outstanding Shares668,000Free Float568,000Market Cap$7.31 million OptionableOptionable Beta1.08 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:NVNO) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enVVeno Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share enVVeno Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
